A variety of different treatment approaches have been used for unresectable metastatic melanoma in the past. Chemotherapy is known to lead to an overall response rate of only 10-15 % and few durable responses. Dacarbazine (DTIC) chemotherapy is an approved and widely used single agent. While it was never established to improve survival compared to supportive care, it has been widely used as a comparator to new drugs in randomized clinical trials [128] .
The findings of Curtin and co-workers of melanomas carrying distinct ''driver'' mutations based on etiologic factors paved the way for a new molecular understanding of melanoma. Activating BRAF mutations have been observed in approximately 40-50 % of all melanomas, particularly in cutaneous melanomas arising on intermittently sun-exposed skin. The majority of BRAF mutations (over 85 %) are located in codon 600, mostly V600E mutations but with a minority of V600K, V600D and V600R mutations, as well as a small number in other codons. Among melanomas that do not have BRAF mutations, 15-20 % harbor NRAS mutations, predominantly Q61R or Q61K mutations. Simultaneous mutations of BRAF and NRAS are highly unusual, [129] presumably because either mutation alone is sufficient to drive the malignant phenotype.
Acral lentiginous melanomas and mucosal melanomas are more likely than other types to harbor activating c-KIT mutations (8-17 % of such tumors). Some of the activating c-KIT mutations are sensitive to treatment with imatinib mesylate, [18] but many are either insensitive to that drug or more sensitive to other kinase inhibitors such as sorafenib or dasatanib.
Current trials on BRAF inhibitors
The oral BRAF inhibitor vemurafenib (Zelboraf Ò , Genentech, South San Francisco, CA) is relatively specific for the V600E mutant form of the BRAF protein. Vemurafenib was approved for treatment of unresectable, BRAF-mutated metastatic melanoma by the FDA in 2011 and by the EMA in Europe in 2012. Phase I and phase II trials [130, 131] demonstrated remarkably high objective response rates, with progression-free survival of about 6 to 7 months and overall survival times of approximately 16 months for vemurafenib-treated patients in first-and second-line settings. In the pivotal phase III trial (BRIM-3), there was a striking difference between vemurafenib-and dacarbazinetreated patients not only for response rate and duration of response, but also for progression-free survival and overall survival. A phase II trial is evaluating vemurafenib in patients suffering from brain metastases with and without previous brain-directed therapies, and other phase II trials are planned for patients with mutations in codon V600 that are not V600E and in children with V600E BRAF mutated melanoma.
At ASCO 2012, the results of the Early Access Program (EAP) for vemurafenib, conducted in various countries, will be presented. The EAP will report particularly on the tolerability of vemurafenib in the setting of the patient's daily routine.
Furthermore, vemurafenib is currently being tested in combination with the anti-CTLA-4 antibody ipilimumab, which was also approved in 2011 for unresectable or metastatic melanoma (regardless of mutation status). It will be interesting to see whether this combination of a rapidly acting drug with a high incidence of eventual resistance developing (vemurafenib) plus a drug ordinarily slow to achieve responses that are nonetheless often durable, can offer a high rate of durable responses in patients with BRAF mutated melanomas. Other approaches to the question of overcoming mechanisms of resistance to BRAF inhibitors are currently being addressed in some study settings. These other early phase clinical trials of vemurafenib are listed on www.clinicaltrials.gov.
Another selective BRAF inhibitor, dabrafenib (GSK221 8436), also showed promising results in phase I/II trials in BRAF-mutated patients. A phase III trial comparing dabrafenib to dacarbazine (BREAK-3) is currently underway. The primary endpoint of this clinical trial is the improvement of progression-free survival (PFS). This allows patients in the chemotherapy arm to cross over after progression during DTIC treatment, something that was not allowed in the vemurafenib phase III trial (BRIM-3). The results of this multinational trial will also be presented at ASCO 2012.
Exciting data on the use of a combination of inhibitors were presented at ASCO 2011. The combination of the BRAF inhibitor dabrafenib and a MEK inhibitor, trametinib (GSK1120212), showed a clinical benefit for almost all treated patients. The response rate was as high as 80 %. It appeared that time to progression is also prolonged compared to single-agent treatment with the BRAF inhibitor, but-while exciting-the data presented at ASCO 2011 were immature. An updated analysis will be presented in 2012. A randomized phase III trial evaluating this promising combination is expected [132] . It is likely that the selective BRAF inhibitors will additionally be tested in adjuvant therapy trials in the near future. Whether singleagent BRAF inhibitors or a combination of a BRAF and MEK inhibitor will be chosen as the appropriate test regimen for a phase III trial is still under discussion.
Current trials on NRAS inhibitors
A MEK inhibitor from Novartis (MEK 162) is currently being tested in patients whose tumors harbor either NRAS or BRAF V600 mutations. MEK162 is a selective inhibitor of the kinases MEK1 and MEK2 and has shown preclinical activity in BRAF-and NRAS-mutant melanoma models. An open-label phase II trial in locally advanced and unresectable or metastatic cutaneous melanoma has been performed. The results will be presented at ASCO 2012.
c-KIT inhibitors
As mentioned previously, some acral lentiginous and mucosal melanomas carry activating c-KIT mutations. Several small reports and phase II trials have shown that imatinib mesylate, an inhibitor of c-KIT, is able to demonstrate objective responses in around 20 % of these patients [133] . An international trial, the TEAM trial (Tasigna Ò Efficacy in Advanced Melanoma) uses a second generation c-KIT inhibitor, nilotinib. The trial was originally designed as randomized phase III trial comparing nilotinib to dacarbazine. However, due to the significantly lower numbers of c-KIT-mutated melanoma patients compared to the initial assumptions and to extremely slow trial recruitment, the study design was changed to a phase II trial using nilotinib only in 2011.
Other drugs in development
Several other drugs, particularly more or less specific inhibitors of key molecules on the various signal transduction pathways of greatest known importance in melanoma, but also multikinase inhibitors and anti-angiogenetic agents, are currently being tested as single agents or in combinational trias. Some multicenter trials are evaluating chemotherapy combined with temsirolimus or everolimus, inhibitors of mTOR. Recently the results of a trial testing the combination of carboplatin and paclitaxel with or without bevacizumab have been released. The BEAM trial, while far from definitive, suggested there may have been some benefit for the patients who got bevacizumab in addition to chemotherapy [134] .
Summary
The discovery of specific mutations in different types of melanomas led to the development and testing of clinically useful inhibitors in a very short time frame. In less than 5 years, selective BRAF inhibitors like vemurafenib were brought from preclinical data via animal models to phase III clinical trials, and now vemurafenib has received approval for treatment of metastatic melanoma. However, this is not considered to be the end, but more the beginning of a new era of melanoma treatment. It is a whole new world for melanoma patients and clinical researchers [135] . Melanoma now serves as a model for targeted therapies and the future of melanoma treatment almost surely lies in treatment combinations. The combination of inhibitors of one signal transduction pathway or of various molecules targeting different signal transduction pathways appears to be particularly attractive. But also the combination of targeted therapies with effective immunotherapeutic agents like the CTLA-4 antibody ipilimumab is an area for active exploration in the near future. The approval of new drugs for unresectable or metastatic melanoma will necessarily lead to new clinical trial endpoints in subsequent studies. There is no question that, despite the availability of newly approved drugs for metastatic melanoma patients, clinical trials will still be mandatory in order to address the goal of cure [135] .
